ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ranolazine

Also written as “Test formulation (Ranolazine extended-release tablets)”, “Reference formulation (Ranolazine extended-release tablets)” and “Ranolazine 500 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Angina Pectoris · Atrial Fibrillation · Coronary Artery Disease · Cardiovascular Diseases, led by 7 companies.

Drug pageRanolazine: every studyMany companies study it; this page follows only the 25 they lead. All 85 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 24, 200825 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences180 open or runningphase 4since Mar 24, 2008Sep 8, 2004none ahead
Menarini Groupits history only20 open or runningphase 2since Feb 10, 2012Feb 10, 2012none ahead
Amit Malhotra, MDits history only10 open or runningphase 4since Jan 26, 2017Jan 26, 2017none ahead
Haisco Pharmaceutical Groupits history only10 open or runningphase 1since Jun 27, 2025Jun 27, 2025none ahead
Novartisits history only10 open or runningphase 2since Mar 21, 2012Mar 21, 2012none ahead
OBS Pakistanits history only10 open or runningphase 4since Mar 15, 2018Mar 15, 2018none ahead
TSH Biopharmits history only10 open or runningno phasesince Jan 7, 2018Jan 7, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Sep 8, 2004.

  1. Mar 24, 2008Phase 4 study in Chronic AnginaNCT00644332 · 172 enrolled · United States
  2. Jan 28, 2009Phase 4 study in Coronary Artery DiseaseNCT00832572 · 5 enrolled · United States
  3. Jul 12, 20102 phase 2 studiesNCT01163734, NCT01163721
  4. Oct 13, 2010Phase 4 study in Myocardial IschemiaNCT01221272 · 81 enrolled · United States, Canada, Czech Republic and more
  5. Apr 11, 2011Phase 4 study in Angina PectorisNCT01334203
  6. Aug 24, 2011Phase 4 study in Angina PectorisNCT01425359 · 949 enrolled · United States, Belarus, Bulgaria and more
  7. Sep 22, 2011Phase 3 study in Coronary Artery DiseaseNCT01442038 · 2,651 enrolled · United States, Austria, Belgium and more
  8. Nov 11, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01472185 · 465 enrolled · United States, Czech Republic, Hungary and more
  9. Dec 15, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01494987 · 431 enrolled · United States, Czech Republic, Hungary and more
  10. Jan 18, 2012Phase 2 study in Atrial FibrillationNCT01522651 · 134 enrolled · United States, Germany, Israel and more
  11. Feb 14, 20122 phase 1 studies in Diabetes Mellitus, Type 2NCT01546597, NCT01546558
  12. Mar 13, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01555164 · 442 enrolled · United States, Canada, Czech Republic and more
  13. Jul 26, 2012Phase 1 study in Renal InsufficiencyNCT01675973 · 4 enrolled · United States
  14. Apr 17, 2013Phase 1 study in Diabetes Mellitus, Type 2NCT01843127 · 24 enrolled · United States

TargetBeta

SCN4A →SCN5A →read by rule
“Sodium channel protein type V alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
QuinidineruleOtsukaphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 18 Gilead Sciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01843127Diabetes Mellitus, Type 2 · United States1CompletedSep 201324
NCT01675973Renal Insufficiency · United States1TerminatedAug 20124
NCT01555164Diabetes Mellitus, Type 2 · United States, Canada, Czech Republic and more3CompletedSep 2013442
NCT01546558Diabetes Mellitus, Type 2 · United States1CompletedMar 201225
NCT01546597Diabetes Mellitus, Type 2 · United States1CompletedMar 201224
NCT01522651Atrial Fibrillation · United States, Germany, Israel and more2CompletedMar 10, 2014134
NCT01494987Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more3CompletedAug 2013431
NCT01472185Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more3CompletedOct 2013465
NCT01442038Coronary Artery Disease · United States, Austria, Belgium and more3CompletedFeb 20152,651
NCT01425359Angina Pectoris · United States, Belarus, Bulgaria and more4CompletedOct 2012949
NCT01334203Angina Pectoris4WithdrawnOct 20120
NCT01221272Myocardial Ischemia · United States, Canada, Czech Republic and more4CompletedSep 201281
NCT01163721Diabetes Mellitus, Type 2 · United States2CompletedNov 201080
NCT01163734Heart Failure, Diastolic · Germany2CompletedFeb 201120
NCT00832572Coronary Artery Disease · United States4TerminatedJun 20095
NCT00644332Chronic Angina · United States4CompletedJan 2011172
NCT00099788Myocardial Ischemia · United States3CompletedFeb 20076,560
NCT00091429Angina Pectoris3CompletedFeb 2005500

How it is read

Names in the registry

  • “Ranolazine”, 24 entries
  • “Test formulation (Ranolazine extended-release tablets)”, 1 entry
  • “Reference formulation (Ranolazine extended-release tablets)”, 1 entry
  • “Ranolazine 500 mg”, 1 entry
  • “Ranolazine plus Metoprolol Combination”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.